Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure.
Forty-seven kittens were exposed for 31 weeks to 12 FeLV-positive carrier cats. The carrier cats were infected with 2 laboratory strains of FeLV and at least 2 strains of street virus. Eleven nonvaccinated control kittens and 12 vaccinated kittens were allotted to 3 groups. After 31 weeks of exposure, the following kittens were persistently blood FeLV positive by ELISA and immunofluorescence antibody (IFA) testing: 7 of the 11 control kittens, 0 of 12 kittens inoculated with vaccine A, 5 of 12 kittens inoculated with vaccine B, and 6 of 12 kittens inoculated with vaccine C. Only the kittens inoculated with vaccine A were significantly (P less than 0.05) different from the control group. After 23 weeks of exposure, culture was done to identify FeLV in the bone marrow of the kittens. Feline leukemia virus was isolated from the bone marrow of 9 of 11 control kittens. Virus was isolated from the bone marrow of 5 of 12 kittens inoculated with vaccine A, 11 of 12 kittens inoculated with vaccine B, and 10 of 12 kittens inoculated with vaccine C. Of the 17 cats that had FeLV isolated only from culture of bone marrow (negative results of blood virus isolation, ELISA, and IFA testing), 13 eliminated the virus from the bone marrow by week 31 of exposure. After 31 weeks of exposure, FeLV was isolated from the bone marrow of 8 of 11 control kittens, 0 of 12 kittens inoculated with vaccine A, 7 of 12 kittens inoculated with vaccine B, and 7 of 12 kittens inoculated with vaccine C.
Legendre
A M
AM
Department of Urban Practice, College of Veterinary Medicine, University of Tennessee, Knoxville 37901.
Hawks
D M
DM
Sebring
R
R
Rohrbach
B
B
Chavez
L
L
Chu
H J
HJ
Acree
W M
WM
D000818:Animals; D001853:Bone Marrow / Q000382:microbiology; D002415:Cats; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005256:Leukemia Virus, Feline / Q000276:immunology* / Q000302:isolation & purification; D016582:Leukemia, Feline / Q000517:prevention & control*; D008297:Male; D011897:Random Allocation; D015682:Retroviridae Proteins, Oncogenic; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary*; D014765:Viral Vaccines; D014766:Viremia / Q000517:prevention & control / Q000662:veterinary
D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine